Spots Global Cancer Trial Database for unresectable
Every month we try and update this database with for unresectable cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Study to Evaluate the Effect of Metformin in the Prevention of HG in HR[+]/HER2[-] PIK3CA-mut Advanced BC Patients | NCT04300790 | Breast Cancer | Alpelisib Metformin Fulvestrant Letrozole Exemestane Vildagliptin Tamoxifen | 18 Years - | MedSIR | |
| A Clinical Trial Investigating the Safety, Tolerability, and Therapeutic Effects of BNT113 in Combination With Pembrolizumab Versus Pembrolizumab Alone for Patients With a Form of Head and Neck Cancer Positive for Human Papilloma Virus 16 and Expressing the Protein PD-L1 | NCT04534205 | Unresectable He... Metastatic Head... Recurrent Head ... | BNT113 Pembrolizumab | 18 Years - | BioNTech SE | |
| Autologous TriMix-DC Therapeutic Vaccine in Combination With Ipilimumab in Patients With Previously Treated Unresectable Stage III or IV Melanoma | NCT01302496 | Malignant Melan... Malignant Melan... | TriMix-DC and i... | 18 Years - | Universitair Ziekenhuis Brussel | |
| Oral Bicarbonate as Adjuvant for Pain Reduction in Patients With Tumor Related Pain | NCT01846429 | Tumor Cancer Pain Malignant Solid... Unresectable Ma... Hematologic Mal... Multiple Myelom... Lymphoma Neoplasm Metast... | Sodium Bicarbon... | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| Study of Intravenous and Intraperitoneal Paclitaxel and Oral Nilotinib for Peritoneal Carcinomatosis From Colorectal, Appendiceal, Small Bowel, Gastric, Cholangiocarcinoma, Breast, Ovarian, or Other Gynecologic Primary Cancer | NCT05185947 | Gynecologic Can... Gynecologic Neo... Peritoneal Carc... Peritoneal Neop... Ovarian Cancer Ovarian Neoplas... Colorectal Canc... Colorectal Neop... Appendiceal Can... Appendiceal Neo... | Paclitaxel Nilotinib | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| CRLX101 Plus Bevacizumab in Advanced RCC | NCT01625936 | Renal Cell Carc... | CRLX101 (Cerule... Bevacizumab | 18 Years - | Abramson Cancer Center at Penn Medicine | |
| MPDL3280A With Chemoradiation for Lung Cancer | NCT02525757 | Lung Cancer Non-Small Cell ... | MPDL3280A Carboplatin Paclitaxel Radiation Thera... | 18 Years - | M.D. Anderson Cancer Center | |
| Study of REGN6569 and Cemiplimab in Adult Patients With Advanced Solid Tumor Malignancies | NCT04465487 | Squamous Cell C... | REGN6569 Cemiplimab | 18 Years - | Regeneron Pharmaceuticals | |
| Effectiveness and Safety Study of TACE Plus Oral Sorafenib for Unresectable HCC | NCT00576056 | Carcinoma, Hepa... | Sorafenib TACE | 18 Years - 100 Years | University of Pittsburgh | |
| Study of Vorinostat in Combination With Gemcitabine and Docetaxel in Advanced Sarcoma | NCT01879085 | Sarcoma | Docetaxel Gemcitabine Vorinostat Pegfilgrastim | 18 Years - | University of Pittsburgh | |
| Trial With Eribulin or Eribulin+ Endocrine Therapy in Locally-recurrent or Metastatic Breast Cancer Patients | NCT03795012 | Breast Cancer | Eribulin | 18 Years - | MedSIR | |
| A Pilot Study for the Treatment of Patients With Metastatic and High Risk Sarcomas and Primitive Neuroectodermal Tumors | NCT00001209 | Neuroectodermal... Neuroepitheliom... Osteosarcoma Sarcoma Sarcoma, Ewing'... | vincristine, ad... | - | National Institutes of Health Clinical Center (CC) | |
| Study of IDO Inhibitor in Combination With Checkpoint Inhibitors for Adult Patients With Metastatic Melanoma | NCT02073123 | Metastatic Mela... Stage III Melan... Stage IV Melano... | Indoximod Ipilimumab Nivolumab Pembrolizumab | 18 Years - | Lumos Pharma | |
| Neoadjuvant Immunotherapy and Chemotherapy Followed by Surgery in Unresectable Stage Ⅲ NSCLC | NCT04943029 | Non Small Cell ... | Carrelizumab Pemetrexed (Non... Carboplatin Surgery | 18 Years - 70 Years | Wuhan Union Hospital, China | |
| Ganitumab in Locally Advanced Unresectable Adenocarcinoma of the Pancreas | NCT01318642 | Adenocarcinoma ... Locally Advance... Unresectable | Gemcitabine AMG 479 Placebo | 18 Years - | Amgen | |
| Cetuximab + Gemox in Biliary Tract Cancer | NCT01216345 | Unresectable Locally Advance... Metastatic | Cetuximab + Gem... | 18 Years - | Association of Research on the Biology of Liver Tumors | |
| A Study of Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma | NCT03430843 | Esophageal Squa... | Tislelizumab Paclitaxel Docetaxel Irinotecan | 18 Years - | BeiGene | |
| A Clinical Trial of Entinostat in Combination With Nivolumab for Patients With Previously Treated Unresectable or Metastatic Cholangiocarcinoma and Pancreatic Adenocarcinoma | NCT03250273 | Metastatic Chol... Cholangiocarcin... Pancreatic Canc... Metastatic Panc... Unresectable Pa... Unresectable Ch... | Entinostat Nivolumab Entinostat Nivolumab | 18 Years - | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| Observation Study: Superselective Drug-Eluting Chemoembolization in Unresectable Intermediate and Advanced HCC Patients | NCT03273608 | Hepatocellular ... | 20 Years - | Taipei Veterans General Hospital, Taiwan | ||
| Treatment With Nab-paclitaxel in Cutaneous SCC | NCT02076243 | Cutaneous Squam... | nab-paclitaxel | 18 Years - | Icahn School of Medicine at Mount Sinai | |
| A Phase II Trial of TPI 287 in Patients Advanced, Unresectable Pancreatic Cancer | NCT00553813 | Pancreatic Canc... | TPI 287 | 18 Years - | Cortice Biosciences, Inc. | |
| Clinical Trial of AMG510 in Stage III Unresectable NSCLC KRAS p.G12C Patients and Ineligible for Chemo-radiotherapy | NCT05398094 | Non-small Cell ... KRAS P.G12C | Sotorasib | 18 Years - | Fundación GECP | |
| Neoadjuvant Combination Chemotherapy of DCS (Cisplatin + Docetaxel + S-1) and DCF (Docetaxel + Cisplatin + 5-FU) in Patients With Locally Advanced Gastric Adenocarcinoma | NCT01286766 | Gastric Cancer | DCS (docetaxel ... DCF (docetaxel ... | 18 Years - 70 Years | Yonsei University | |
| Nab-Paclitaxel in Combination With Carboplatin as First-line Therapy in Patients With NSCLC | NCT02799862 | Carcinoma, Non-... | Nab-Paclitaxel Carboplatin | 18 Years - 99 Years | iOMEDICO AG | |
| Intraoperative Celiac Plexus Neurolysis for Patients With Operable Pancreatic and Periampullary Cancer | NCT00806611 | Pancreatic Canc... | Alcohol Block | 18 Years - | Thomas Jefferson University | |
| Oxaliplatin/Irinotecan/Bevacizumab Followed by Docetaxel/Bevacizumab in Inoperable Locally Advanced or Metastatic Gastric Cancer Patients | NCT00952003 | Gastric Cancer Unresectable | Oxaliplatin, Ir... | 18 Years - | Arbeitsgemeinschaft medikamentoese Tumortherapie | |
| Combined BRAF-Targeted Therapy & Immunotherapy for Melanoma | NCT01754376 | Melanoma | Aldesleukin Vemurafenib | 18 Years - | Massachusetts General Hospital | |
| FOLFIRINOX for Unresectable Locally Advanced and Borderline Resectable Pancreatic Cancer | NCT01688336 | Pancreatic Canc... | FOLFIRINOX | 18 Years - | UNC Lineberger Comprehensive Cancer Center | |
| Fecal Microbiota Transplant (FMT) in Melanoma Patients | NCT03341143 | Melanoma | Fecal Microbiot... | 18 Years - | University of Pittsburgh | |
| A Study to Evaluate Adaptive Dosing of Ipilimumab and Nivolumab Combination Immunotherapy | NCT03122522 | Metastatic Mela... | ipilimumab nivolumab | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Study in Patients With Unresectable And Metastatic Melanoma: The Optimize Study | NCT02780089 | Melanoma | 18 Years - | Bristol-Myers Squibb | ||
| TIGER-3: Open Label, Multicenter Study of Rociletinib (CO-1686) Mono Therapy Versus Single-agent Cytotoxic Chemotherapy in Patients With Mutant EGFR NSCLC Who Have Failed at Least One Previous EGFR-Directed TKI and Platinum-doublet Chemotherapy | NCT02322281 | Non-small Cell ... | Rociletinib Pemetrexed or g... | 18 Years - | Clovis Oncology, Inc. | |
| Colectomy in Patients With Asymptomatic and Unresectable Stage IV Colon Cancer | NCT02363049 | Malignant Neopl... Colon Cancer Li... | Colectomy Chemotherapy | 18 Years - 75 Years | Assistance Publique - Hôpitaux de Paris | |
| Immunonutrition to Reduce Toxicities in Non-Small Cell Lung Cancer | NCT03628144 | Non Small Cell ... NSCLC Non-small Cell ... Non-small Cell ... Non-small Cell ... NSCLC Stage III... NSCLC, Stage II... | Impact® Advance... Boost® High Pro... Radiation Thera... Chemotherapy Quality of life... Evaluation of C... Mindfulness Que... | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| Aroplatin and Capecitabine in Patients With Advanced Colorectal Cancer Resistant to Standard Therapies | NCT00081536 | Colorectal Neop... | Aroplatin (Lipo... | 18 Years - | Aronex Pharmaceuticals | |
| Study of Pasireotide Long Acting Release (LAR) in Patients With Metastatic Neuroendocrine Tumors (NETs) | NCT01253161 | Neuroendocrine ... Carcinoid Tumor... | Pasireotide Lon... | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| Anlotinib Hydrochloride Versus Imatinib Mesylate in Locally Advanced, Unresectable or Metastatic Chordoma | NCT04042597 | Effect of Drugs Quality of Life Chordoma Advanced Cancer | Anlotinib Hydro... | 18 Years - | Peking University People's Hospital | |
| A Trial of Pembrolizumab and Metformin Versus Pembrolizumab Alone in Advanced Melanoma | NCT03311308 | Advanced Melano... | Pembrolizumab I... Metformin | 18 Years - | University of Pittsburgh | |
| A Pilot Study of OncoSil™ Given to Patients With Pancreatic Cancer Treated With FOLFIRINOX or Gemcitabine+Abraxane | NCT03003078 | Unresectable Lo... | OncoSil™ | 18 Years - | OncoSil Medical Limited | |
| A Phase 1 Study of the Clinical and Immunologic Effects of ALT-803 in Patients With Advanced Solid Tumors | NCT01946789 | Advanced Solid ... | ALT-803 | 18 Years - | Altor BioScience | |
| Tumor-Infiltrating Lymphocytes And Low-Dose Interleukin-2 Therapy Following Cyclophosphamide And Fludarabine In Patients With Melanoma | NCT01883323 | Metastatic, Sta... | Cyclophosphamid... Fludarabine Tumor-Infiltrat... Low-Dose Interl... | 18 Years - | University Health Network, Toronto | |
| Trial Comparing PLA to HIGRT (PROVE-HCC) | NCT03402607 | Hepatocellular ... | Percutaneous Lo... Hypofractionate... | 18 Years - | Duke University | |
| A Study of Axitinib in Advanced Carcinoid Tumors | NCT01435122 | Carcinoid Tumor | Axitinib | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| PD-L1 Expression in Advanced Osteosarcoma | NCT03582527 | Progression Survival | all study parti... | - | Peking University People's Hospital | |
| A Study to Evaluate KIN-2787 in Participants With BRAF and/or NRAS Mutation Positive Solid Tumors | NCT04913285 | Solid Tumor, Ad... Non-small Cell ... Melanoma | KIN-2787 KIN-2787 and bi... | 18 Years - | Pierre Fabre Medicament | |
| A Phase 1 Study of the Clinical and Immunologic Effects of ALT-803 in Patients With Advanced Solid Tumors | NCT01946789 | Advanced Solid ... | ALT-803 | 18 Years - | Altor BioScience | |
| STA-9090(Ganetespib) in Patients With Unresectable Stage III or Stage IV Melanoma | NCT01551693 | Melanoma | STA-9090 | 18 Years - | Dana-Farber Cancer Institute | |
| Capecitabine (NX) Versus Docetaxel Plus Capecitabine (TX) as 1-line Chemotherapy on Metastatic Breast Cancer (MBC) | NCT01126138 | Carcinoma, Inva... | Vinorelbine plu... Docetaxel plus ... | 18 Years - | ChineseAMS | |
| Marrow Infiltrating Lymphocytes - Non-Small Cell Lung Cancer (MILs™ - NSCLC) Alone or in Combination With Nivolumab With or Without Tadalafil in Locally Advanced and Unresectable or Metastatic NSCLC | NCT04069936 | Non Small Cell ... Lung Cancer Lung Cancer Met... Lung Cancer, No... Non Small Cell ... NSCLC Non-small Cell ... Non-small Cell ... | MILs™ - NSCLC nivolumab tadalafil | 18 Years - | WindMIL Therapeutics | |
| Sorafenib and Temsirolimus in Treating Patients With Metastatic, Recurrent, or Unresectable Melanoma | NCT01851408 | Melanoma Recurrent Melan... Stage III Melan... Stage IV Melano... | sorafenib tosyl... temsirolimus | 18 Years - | National Cancer Institute (NCI) | |
| Phase I Trial of Combination of FOLFIRI and SOM 230 | NCT01434069 | Gastrointestina... | SOM230C LAR FOLFIRI Infusio... | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| SIRT for Potentially Resectable HCC | NCT05994859 | Hepatocellular ... | SIRT | 18 Years - 75 Years | Second Affiliated Hospital of Guangzhou Medical University | |
| Study of Tivantinib in Subjects With Inoperable Hepatocellular Carcinoma (HCC) Who Have Been Treated With One Prior Therapy | NCT01755767 | Hepatocellular ... | Tivantinib Placebo | 18 Years - | Daiichi Sankyo | |
| A Study of Axitinib in Advanced Carcinoid Tumors | NCT01435122 | Carcinoid Tumor | Axitinib | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| IMCgp100 in Advanced Unresectable Melanoma | NCT01209676 | Melanoma Advanced Diseas... Unresectable | IMCgp100 inject... | 18 Years - | University of Pennsylvania | |
| A Safety and Effectiveness Study of Aroplatin in Patients With Advanced Colorectal Cancer Resistant to Standard Therapies | NCT00043199 | Colorectal Neop... | Aroplatin (Lipo... | 18 Years - | Aronex Pharmaceuticals | |
| An Open-label, Phase I/II Study of PLENA Regimen in Patients With Unresectable Pancreatic Cancer or BTC | NCT05327582 | Pancreatic Canc... Biliary Tract C... | Durvalumab Lenvatinib Nab paclitaxel | 18 Years - 75 Years | Chinese PLA General Hospital | |
| Proton Radiation for Unresectable, Borderline Resectable, or Medically Inoperable Carcinoma of the Pancreas | NCT02598349 | Pancreatic Canc... | Proton Radiatio... Capecitabine Surgical resect... | 18 Years - | Proton Collaborative Group | |
| LifePearl-Doxo Pharmacokinetic (PK) Study | NCT02548780 | HCC Hepatocellular ... | Chemoembolizati... Pharmacokinetic... | 18 Years - | Terumo Europe N.V. | |
| Nintedanib as Switch Maintenance Treatment of Pleural Malignant Mesothelioma | NCT02863055 | Malignant Pleur... | Nintedanib Placebo | 18 Years - 90 Years | European Organisation for Research and Treatment of Cancer - EORTC | |
| Fecal Microbiota Transplant (FMT) in Melanoma Patients | NCT03341143 | Melanoma | Fecal Microbiot... | 18 Years - | University of Pittsburgh | |
| Inhaled Doxorubicin Plus IV Docetaxel and Cisplatin in Patients With Non-Small-Cell Lung Carcinoma (NSCLC) | NCT00082472 | NSCLC | Doxorubicin HCl... Docetaxel Cisplatin | 18 Years - | Zivena | |
| A Beta-only IL-2 ImmunoTherapY Study | NCT05086692 | Advanced Solid ... Unresectable So... Clear Cell Rena... Triple Negative... Non-Small Cell ... Non-Small Cell ... Colorectal Canc... Gastric Cancer Cervical Cancer Basal Cell Carc... Bladder Cancer Merkel Cell Car... Squamous Cell C... Cutaneous Squam... Pleural Mesothe... Esophageal Canc... Endometrial Car... Solid Tumor Solid Tumor, Ad... MSI-H Solid Mal... Cancer With A H... Epithelial Ovar... Primary Periton... Gastroesophagea... Acral Melanoma Mucosal Melanom... Cutaneous Melan... DMMR Solid Mali... Fallopian Tube ... Ovarian Cancer MSI-H Cancer DMMR Cancer Pancreas Adenoc... Skin Cancer | MDNA11 Pembrolizumab | 18 Years - | Medicenna Therapeutics, Inc. | |
| HER3-DXd (Patritumab Deruxtecan; U3-1402) in Combination With Osimertinib in Subjects With Locally Advanced or Metastatic EGFR-mutated Non-Small Cell Lung Cancer | NCT04676477 | Non-Small Cell ... | HER3-DXd HER3-DXd Osimertinib Osimertinib HER3-DXd HER3-DXd Osimertinib | 18 Years - | Daiichi Sankyo | |
| Induction Gemcitabine & Carboplatin Followed by Paclitaxel & Carboplatin +XRT in NSCLC | NCT00226590 | Lung Cancer | Gemcitabine Carboplatin Paclitaxel Radiation | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| A Study of Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma | NCT03430843 | Esophageal Squa... | Tislelizumab Paclitaxel Docetaxel Irinotecan | 18 Years - | BeiGene | |
| Neoadjuvant Immunotherapy and Chemotherapy Followed by Surgery in Unresectable Stage Ⅲ NSCLC | NCT04943029 | Non Small Cell ... | Carrelizumab Pemetrexed (Non... Carboplatin Surgery | 18 Years - 70 Years | Wuhan Union Hospital, China | |
| Study of Pasireotide Long Acting Release (LAR) in Patients With Metastatic Neuroendocrine Tumors (NETs) | NCT01253161 | Neuroendocrine ... Carcinoid Tumor... | Pasireotide Lon... | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| Study of Efficacy and Safety of Novel Spartalizumab Combinations in Patients With Previously Treated Unresectable or Metastatic Melanoma | NCT03484923 | Melanoma | PDR001 LAG525 INC280 ACZ885 LEE011 | 18 Years - | Novartis | |
| Study of PI3Kinase Inhibition (Copanlisib) and Anti-PD-1 Antibody Nivolumab in Relapsed/Refractory Solid Tumors With Expansions in Mismatch-repair Proficient (MSS) Colorectal Cancer | NCT03711058 | Unresectable or... Colon Cancer | Copanlisib Nivolumab | 18 Years - | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| Study of XL888 With Vemurafenib for Patients With Unresectable BRAF Mutated Stage III/IV Melanoma | NCT01657591 | Melanoma | XL888 Vemurafenib | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| Proton Radiation for Unresectable, Borderline Resectable, or Medically Inoperable Carcinoma of the Pancreas | NCT02598349 | Pancreatic Canc... | Proton Radiatio... Capecitabine Surgical resect... | 18 Years - | Proton Collaborative Group | |
| TIGER-3: Open Label, Multicenter Study of Rociletinib (CO-1686) Mono Therapy Versus Single-agent Cytotoxic Chemotherapy in Patients With Mutant EGFR NSCLC Who Have Failed at Least One Previous EGFR-Directed TKI and Platinum-doublet Chemotherapy | NCT02322281 | Non-small Cell ... | Rociletinib Pemetrexed or g... | 18 Years - | Clovis Oncology, Inc. | |
| Parallel Phase I/II Trial of Decitabine and Peg-Interferon in Melanoma: Phase I Portion | NCT00791271 | Melanoma | Decitabine Pegylated Inter... | 18 Years - | M.D. Anderson Cancer Center | |
| LifePearl-Doxo Pharmacokinetic (PK) Study | NCT02548780 | HCC Hepatocellular ... | Chemoembolizati... Pharmacokinetic... | 18 Years - | Terumo Europe N.V. | |
| TACE and SBRT Followed by Double Immunotherapy for Downstaging Hepatocellular Carcinoma | NCT04988945 | HCC | TACE SBRT Durvalumab Tremelimumab | 18 Years - | The University of Hong Kong | |
| Botensilimab and Balstilimab Optimization in Colorectal Cancer | NCT06268015 | Colorectal Canc... | Botensilimab Balstilimab Oxaliplatin Leucovorin Fluorouracil Bevacizumab Panitumumab | 18 Years - | Duke University | |
| Induction Chemotherapy Using Paclitaxel, Carboplatin, CPT-11 With Pegfilgrastim | NCT00280787 | Non Small Cell ... | Paclitaxel Carboplatin CPT-11 Pegfilgrastim Conformal radio... | 18 Years - | UNC Lineberger Comprehensive Cancer Center | |
| TKM 080301 for Primary or Secondary Liver Cancer | NCT01437007 | Colorectal Canc... Pancreas Cancer... Gastric Cancer ... Breast Cancer W... Ovarian Cancer ... | TKM-080301 | 18 Years - 99 Years | National Institutes of Health Clinical Center (CC) | |
| Nimotuzumab Plus S1 Versus Placebo Plus S1 as Maintenance Treatment in Patients With Unresectable Pancreatic Cancer | NCT02945267 | Unresectable Pa... | Nimotuzumab plu... Placebo plus S1 | 18 Years - 75 Years | Chinese PLA General Hospital |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
